Fcγ Receptors in Solid Organ Transplantation

Tomas Castro-Dopico & Menna R. Clatworthy

Published online: 3 October 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract In the current era, one of the major factors limiting graft survival is chronic antibody-mediated rejection (ABMR), whilst patient survival is impacted by the effects of immunosuppression on susceptibility to infection, malignancy and atherosclerosis. IgG antibodies play a role in all of these processes, and many of their cellular effects are mediated by Fc gamma receptors (FcγRs). These surface receptors are expressed by most immune cells, including B cells, natural killer cells, dendritic cells and macrophages. Genetic variation in FCGR genes is likely to affect susceptibility to ABMR and to modulate the physiological functions of IgG. In this review, we discuss the potential role played by FcγRs in determining outcomes in solid organ transplantation, and how genetic polymorphisms in these receptors may contribute to variations in transplant outcome.

Keywords Antibodies · IgG · Fcγ receptors · Antibody-mediated rejection · Single nucleotide polymorphisms · Infection

Introduction

Immunoglobulin G (IgG) antibodies are the most abundant immunoglobulin isotype in human serum and extracellular tissue fluid. They play an important role in defence against infection via pathogen neutralisation and opsonisation and complement activation, and can directly stimulate a wide variety of immune cells by cross-linking cell surface Fc gamma receptors (FcγRs) [1, 2]. However, autoantibodies are pathogenic in a number of autoimmune diseases [3, 4] and in solid organ transplantation alloantibodies are associated with antibody-mediated rejection (ABMR) [5, 6]. Indeed, in the current era, the presence of donor-specific anti-HLA antibodies (DSA) represents a major hurdle in transplantation. Sensitised transplant recipients with pre-formed DSA now make up a third of wait-listed kidney transplant recipients, and have a significantly increased risk of acute and chronic ABMR, resulting in reduced allograft survival [7, 8]. In non-sensitised subjects, the development of de novo DSA is also associated with worse outcome, particularly if they occur many years after the transplant [9, 10].

With accumulating evidence of the deleterious effects of IgG DSA on long-term allograft survival, there has been increased interest in understanding the mechanisms that drive tissue damage in the context of ABMR. The observation of CD4d deposition in the peritubular capillaries of biopsies with histological changes of ABMR and DSA led to the assumption that complement activation plays a key role in antibody-associated allograft damage. However, the absence of C4d staining in more than half of biopsies with late ABMR highlights the importance of complement-independent mechanisms in mediating the deleterious effects of DSAs [11, 12]. Furthermore, some IgG isotypes (IgG4) cannot fix complement, whilst IgG2 has a limited complement-activating capacity compared with IgG1 and IgG3 [13]. Reed and colleagues have produced an elegant body of work demonstrating that HLA antibodies can have direct effects on allograft endothelial cells via variable region binding [14], but the engagement of FcγRs on immune cells and on endothelium is also likely to be of critical importance in generating alloantibody associated inflammation.

This article is part of the Topical Collection on Immunology

Menna R. Clatworthy
mrc38@cam.ac.uk
Tomas Castro-Dopico
tc424@cam.ac.uk

1 Molecular Immunity Unit, Department of Medicine, MRC Laboratory of Molecular Biology, University of Cambridge, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK

© Springer
(Fig. 1a). FcyRs bind to the Fc portion of IgG and mediate the activation of both innate and adaptive immune cells. Variation in the genes encoding these receptors can alter IgG binding to FcyRs and receptor activity, and may therefore influence the magnitude of inflammation induced by alloantibodies as well as the risk of developing alloantibodies.

Although chronic ABMR represents a major challenge to graft survival, one of the commonest causes of graft loss in the long-term is death of the transplant recipient with a functioning graft. This most frequently occurs in the context of infection, malignancy or cardiovascular disease, all of which may be influenced by humoral immunity. In the case of infection and malignancy, IgG antibodies may have beneficial effects [15, 16], whilst in atherosclerosis their function is less clear [17–19], with FcyRs again playing a key role.

In this review, we discuss the impact of FcyRs on immune cell activation and consider their potential impact in transplant rejection and recipient survival. Given the clinical and therapeutic similarities between ABMR and IgG-mediated autoimmune diseases, such as systemic lupus erythematosus (SLE), many of the data identifying the cellular mechanisms underpinning the pathogenic effects of antibody may inform discussions. We will therefore also consider this evidence, where relevant to antibody-mediated pathology in transplantation.

### Fcy Receptors—Overview and Cell Distribution

FcyRs are cell surface molecules that bind to the Fc portion of IgG antibodies to initiate intracellular signalling pathways, one with high affinity (FcyRI), capable of binding monomeric IgG. There is a single inhibitory receptor, FcyRIIB, with an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM). C Cellular distribution and function of FcyRs—FcyRs are expressed across numerous immune cells implicated in ABMR, and promote cell type-specific immunological mechanisms that could contribute to allograft rejection, including endothelial adhesion, ADCC, pro-inflammatory cytokine production and ROS production.
leading to immune cell maturation and activation. In humans, there are several activating receptors (FcγRIIA, FcγRIIC, FcγRIIIA and FcγRIIIB) and a single inhibitory receptor, FcγRIIB, which plays a critical role in suppressing IgG-mediated inflammation [1, 20] (Fig. 1b). FcγRs are widely expressed on immune cells, including neutrophils, monocytes, macrophages, dendritic cells (DCs), mast cells, natural killer (NK) cells and B cells, but the type of FcγRs expressed differs between cell types (Fig. 1c). Notably, T cells do not express FcγRs. In addition to binding IgG, FcγRIIA can also bind to acute phase response proteins, C-reactive protein (CRP) [21•] and serum amyloid P (SAP) [22].

Most FcγRs are low-to-medium affinity for IgG, requiring cross-linking of several receptors into signalling synapses on the cell surface in order to initiate productive signalling. This is achieved through the formation of high avidity immune complexes (IC) between antigen and antigen-specific IgG or by IgG-opsonised cells. The absence of signalling upon ligation of monomeric IgG prevents inappropriate immune cell activation, which is critical, given the abundance of circulating monomeric IgG. The inhibitory receptor, FcγRIIB, acts as an additional regulatory mechanism to suppress IgG-mediated inflammation, although its expression is heterogeneous across cells of the immune system and subject to regulation by various stimuli, particularly by the cytokine milieu [23, 24]. For example, Th2 cytokines such as IL-4 and IL-33 increase monocyte expression of FcγRIIB [23, 25••], whilst interferon-γ (IFNγ) leads to a reduction in FcγRIIB expression on monocytes and DCs [26]. The ratio of activating to inhibitory FcγRs on any given cell is known as the activating/inhibitory (A/I) ratio, and its context-specific modulation allows for appropriate immune responses to be raised [1, 27]. Genetic polymorphisms in human FCGR genes that alter receptor expression or function are frequently associated with differential susceptibility to both infection and autoimmunity [15, 20, 27]. Genetic variation in FcγRs is not the only factor that influences the outcome for a cell encountering IgG immune complexes; differences in IgG glycosylation can alter affinity for activating versus inhibitory FcγRs [28–31]; for example, de-fucosylation increases the binding affinity of IgG for activating FcγRIIA (but not FcγRIIIB) 10–50 fold [32]. Data indicate abnormalities in the IgG glycome in some patients with SLE, with a reduction in galactosylation and sialylation of IgG that might potentially favour binding to activating FcγR [33]. A reduction in galactosylation has also been observed in patients with rheumatoid arthritis [34], but there is currently no information on whether differences in the glycosylation state of DSA might impact their pathogenicity.

FcγR Signalling

Activating FcγR cross-linking leads to tyrosine phosphorylation of the immunoreceptor tyrosine-based activating motif (ITAM) within the associated common Fcγ chain by the Src-kinases Lyn and subsequent recruitment of SH2-containing kinases [35]. This ultimately leads to the activation of phosphatidylinositol3-kinase (PI3-K) and phospholipase-Cγ (PLCγ), which trigger protein kinase C (PKC) and a calcium flux. The downstream effect of this activating signalling cascade varies between immune cells (Fig. 1c).

In contrast to activating FcγRs, FcγRIIB contains an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM). Cross-linking of FcγRIIB with activating FcγR leads to ITIM phosphorylation by Src kinases, recruiting inositol phosphatases, most notably SHIP1, to neutralise activating signals [36]. Thus, activation and inhibitory FcγRs are co-expressed on the majority of immune cells, and their relatively low level of expression allows the cell to modulate the activation threshold of a cell encountering immune complexes. FcγRIIB dysfunction, therefore, has the potential to mediate numerous inflammatory processes in ABMR, including the persistence of DSA-producing plasma cells in the periphery and the local activation of infiltrating immune cells within the allografts.

FcγR Function in Immune Cells

A number of immune cells have been implicated in the pathogenesis of ABMR, including neutrophils, macrophages, and NK cells. FcγR cross-linking by IgG IC are known to profoundly impact the function of these cells. Furthermore, human endothelial cells can also express FcγRs [37].

Neutrophils Human neutrophils constitutively express FcγRIIA and FcγRIIB, a GPI-linked receptor. Non-activated neutrophils express FcγRIIB2 mRNA [23, 38] but minimal cell-surface levels of FcγRIIB2 [39•]. Similarly, in mouse neutrophils, there is low fcyrb mRNA in bone marrow and blood neutrophils, but expression is significantly increased following activation [40]. Cross-linking of activating FcγRs on neutrophils leads to phagocytosis, cytokine and superoxide production, increased neutrophil adhesion to endothelial cells and neutrophil extracellular trap formation (NETosis) [41–46].

Macrophages Macrophages are myeloid cells specialised for phagocytosis that may be tissue-resident (including Kupffer cells in the liver and alveolar macrophages in the lungs) or may differentiate from newly recruited monocytes during local inflammation. Most tissue-resident macrophages express activating FcγRs (FcγRIIA and FcγRIIIA) and FcγRIIB, with the balance tipped in favour of activating FcγR expression. Engagement of activating FcγRs in macrophages results in phagocytosis and cytokine release (including tumour necrosis factor (TNF), IL-6, IL-1α and neutrophil chemoattractants)
[47], and the magnitude of this response is controlled by FcγRIIB [48–51].

**Dendritic Cells** DCs express FcγRIIA and FcγRIIIB but in contrast to macrophages, in immature DCs, expression of the inhibitory FcγRIIB dominates. DC maturation signals, such as LPS or IFN-γ, down-regulate FcγRIIB such that IgG-opsonised antigen may be rapidly internalised by activating FcγRs and processed for presentation to T cells, and results in the production of inflammatory cytokines [26, 52, 53]. Furthermore, IgG immune complexes promote DC migration along lymphatics [54••]. FcγRIIB expression on DCs suppresses IC-mediated pro-inflammatory cytokine release, T cell stimulation and migration [55, 54••, 56].

**NK Cells** FcγRIIC and FcγRIIIA expression by NK cells is required for antibody-dependent cellular cytotoxicity (ADCC), whereby cytotoxic granules are released to kill IgG-opsonised cells, but these cells do not express the inhibitory FcγRIIB [57, 58]. As well as ADCC, NK cells undergo IFN-γ release following FcγR cross-linking.

**B Cells and Plasma Cells** FcγRIIB is the only FcγR expressed by B cells, where it cross-links to the B cell receptor (BCR) to increase the B cell activation threshold and suppress antibody production [20]. Furthermore, direct cross-linking of FcγRIIB on the surface of mature B cells and bone marrow-resident plasma cells can directly mediate apoptosis, thereby limiting the peripheral pool of antibody-producing cells [59].

**Endothelial Cells** DSAs can directly mediate endothelial cell activation and proliferation via binding to surface MHC [60, 61]. These effects may be further augmented by simultaneous binding to FcγRs, increasing the expression of adhesion molecules that allow leukocyte recruitment [62]. FcγRI and FcγRII expression on cultured human aortic endothelial cells was shown to mediate IgG internalisation, cytokine production, up-regulation of adhesion molecules and activation by CRP in vitro [63]. Furthermore, FcγRIIB has been implicated in the pathogenesis of obesity-induced hypertension, via IgG-mediated attenuation of endothelial NO synthase activity [64]. The extent of FcγR expression on renal endothelial cells is less clear [65]. However, TNF-α and IFN-γ enhance FcγR expression by human endothelial cells in vitro, and this may have added importance in the context of allograft rejection [37].

**FcγRs and ABMR**

There are a number of lines of evidence to suggest that FcγRs may mediate inflammation in ABMR as follows:

1. **Mouse models**—Mice deficient in activating FcγRs are protected from antibody-mediated autoimmune pathology, whilst those deficient in the inhibitory receptor FcγRIIB have more aggressive disease [1, 20]. FcγRIIB-deficient mice have been subjected to a murine cardiac allograft model (BM12 organs into C57BL/6 mice). In this model, a chronic vasculopathy is observed, analogous to that in human hearts with chronic rejection, which is driven by autoantibody production. FcγRIIB-deficient mice demonstrated elevated autoantibody production and more severe arteriopathy [66•]. These data are consistent with the known role for FcγRIIB in regulating B cells, but this study did not dissect the relative effect of FcγRIIB on B cells versus myeloid cells. Of note, myeloid-specific FcγRIIB deficiency is sufficient to exacerbate tissue inflammation in a model of antibody-mediated glomerulonephritis [67].

2. **Histological appearances in ABMR**—Although this represents circumstantial evidence, the classical histological features of acute renal ABMR demonstrate the presence of cells known to express FcγRs, including neutrophils within peritubular capillaries and monocytic infiltration of the endothelium and glomeruli. Indeed, the presence of glomerular monocytes in ABMR was associated with worse outcomes, independent of C4d staining [68, 69] and in cardiac allografts with ABMR, a significantly increased number of macrophages has been observed [70]. NK cells are present in the microvascular endothelium in patients with ABMR, a major site of DSA deposition, where ADCC of endothelial cells may directly contribute to graft rejection. Furthermore, NK cell-derived IFNγ (a cytokine known to be produced by NK cells upon FcγR cross-linking) has been implicated in driving a positive feedback loop, in which HLA expression on endothelial cells is enhanced, resulting in further DSA deposition and local immune cell activation [71, 72].

Expanded lymphatic vasculature and mononuclear cell aggregation, including tertiary lymphoid organs have been observed within rejected allografts [73]. IgG immune complexes can induce VEGF-A production by macrophages, driving lymphangiogenesis in vivo, and represents another potential mechanism by which DSA might impact allograft rejection [74].

3. **Transcriptomic signatures in ABMR—FCGR3A transcripts are enriched within renal transplant biopsies, and correlate with the presence of DSA and ABMR. Given the enrichment of other NK cell-associated transcripts, this supports the role of ADCC within chronically rejecting allografts [71, 72, 75•].** FcγRIIIA is also expressed by myeloid cells, and an increase in some macrophage-associated transcripts has also been observed in ABMR, including CX3CR1 and IL1B, suggesting a
potentially contributes to FcyR-mediated inflammation within allografts.

4. **Genetic association studies in transplantation**—A number of SNPs have been identified in both activating and inhibitory FcyRs (Table 1). This region of the genome is also subject to copy number variation. A non-synonymous SNP in FcyRIIA (rs1801274) encodes a histidine to arginine amino acid substitution in the extracellular domain of the receptor (FcyRIIA-H131R). This is associated with a significant reduction in the IgG binding affinity of the receptor. In particular, FcyRIIA-131H is the only human FcyR that binds IgG2 effectively, whilst FcyRIIA-131R binds IgG2 weakly. A SNP in FcyRIIIA (rs396991), encoding a valine for a phenylalanine at amino acid 158 in the extracellular domain of the receptor (FcyRIIIA-F158V) also significantly impacts IgG binding. FcyRIIIA-158V has higher affinity for IgG1 and IgG3 than FcyRIIIA-158F [15, 27].

Several groups have examined activating FcyR SNPs in kidney transplant recipients, although the number included in these case-control studies are small [76–80]. Allograft survival was increased in patients with the FcyRIIA-131R/R genotype [76], but in two subsequent studies this genotype was associated with acute rejection [78, 79], the latter postulated to be due to reduced disposal of deposited IgG. No significant association with FcyRIIA genotype was observed [79]. Similarly, in a larger study of 200 kidney transplant recipients who had lost their grafts, the FcyRIIA-131R/R genotype was associated with early graft loss (<60 months) and shorter graft survival, particularly in patients who were DSA positive [80]. These genetic data are in contrast to cellular studies demonstrating that monocytes from individuals with the FcyRIIA-131H/H genotype adhered more readily to HLA antibody-activated endothelium compared with FcyRIIA-131R/R monocytes [62], an effect most obvious in the presence of IgG2 DSA. The authors propose that the contrasting results relate to the impact of FCGR SNPs on the efficacy of induction therapy, but in the study by Valenzuela et al. non-depleting anti-CD25 antibodies were used, which would not be influenced by FcyR polymorphisms [62]. These conflicting results certainly emphasise the need for more accurate phenotyping of patients included in genetic studies of the FCGR locus. Ideally this would include not only routine screening for DSA, but also an assessment of the IgG subclass and the glycosylation of IgG, factors that have a profound impact on the functional significance of genetic polymorphisms.

In humans, a number of non-synonymous SNPs have been identified in the *FCGR2B* gene, of which, only one occurs at a notable frequency (rs1050501). This SNP encodes an isoleucine-to-threonine substitution at position 232 within the transmembrane domain of the receptor, resulting in loss of function [81••, 82]. FcyRIIB-232T is a major risk factor for SLE [83]. Indeed, immune cells isolated from FcyRIIB-232T/T homozygous individuals display heightened immune responses to IgG-IC [81••, 84]. However, in a large study of more than 2800 renal transplant recipients, no association was observed between the autoimmune-associated SNP FcyRIIB-232T and allograft or patient survival [85]. While this supports the hypothesis that FcyRIIA on NK cells may be the prominent driver of chronic ABMR (FcyRIIB is not expressed by NK cells (Fig. 1c), a lack of patient stratification (including an inability to identify patients with DSA or ABMR), may have masked any effects.

**FcyRs and Recipient Survival**

**Infection**

In murine models, resistance to infection is intimately linked to FcyR activity [86]. Overall, activating receptor SNPs with increased IgG binding (FcyRIIA-131H, FcyRIIIA-158V) are associated with reduced susceptibility to infection [15, 86], whilst a reduction in FcyRIIB activity increases defence against bacterial [50, 81••, 87], mycobacterial [88], viral [89] and parasitic infection [83, 84]. However, the role of human

| Receptor  | Alleles         | Effect                                      |
|-----------|-----------------|---------------------------------------------|
| FcyRIIA   | H/R131          | Increased IgG1 and IgG2 affinity (H131)     |
|           | FcyRIIA-exon 6  | Enhanced cellular activation                |
| FcyRIIB   | I/T232          | Impaired inhibitory signalling (T232)       |
|           | −386G/C         | Altered *FCGR2B* promoter activity          |
|           | −120T/A         |                                             |
| FcyRIIC   | STOP/Q13        | Altered cell surface expression of FcyRIIB/C|
| FcyRIIIA  | V/F-158         | Reduced antigen affinity (F158)             |
| FcyRIIB   | NA1/NA2/SH      | Increased antigen affinity (NA1)            |
|           |                 | Increased surface FcyRIIB expression       |
FCGR SNPs on susceptibility to post-transplant infections is yet to be completely elucidated.

FcyRIIA can also bind to acute phase response proteins [21•, 22] that can opsonise pathogens. Unlike IgG, FcyRIIA affinity for CRP is actually reduced in individuals homozygous for FcγRIIA-131H and this may influence outcomes in infection. In a study of post-operative infection in liver transplant patients, individuals that were dually homozygous for the FcγRIIA-131H/H, polymorphism and the polymorphism in FCGR3A (F/F158 that reduces IgG binding affinity) were susceptible to blood-borne infections and increased mortality. This susceptibility was attributed to a reduced binding and clearance of CRP-opsonised bacteria, resulting in overwhelming infection [90•].

Fig. 2 Variation in activating and inhibitory FcγR expression and IgG binding affinity alters inflammation, responses to infection and antibody production. SNPs in human FCGR genes that lead to higher affinity of activating FcγR for IgG (FcγRIIA-131H, FcγRIIA-158V) or reduced inhibitory receptor function (FcγRIIB-232T) result in an increased A/I ratio. In the presence of deposited alloantibody, this can drive allograft inflammation through ADCC, cytokine release, and immune cell adhesion, as well as by lowering the threshold for B cell activation and survival in the periphery. However, a high A/I ratio may also promote DSA clearance by mononuclear phagocytes, contributing to the resolution of inflammation and enhance resistance to secondary complications, such as infection and malignancy.

Malignancy

Malignancies occur at increased frequency in transplant recipients, particularly skin malignancies and those caused by oncogenic viruses, including post-transplant lymphoproliferative disorder (PTLD). Murine models have demonstrated that IgG opsonised tumour antigens may be effectively processed by DCs to induce anti-tumour responses in an FcγR-dependent manner [91, 92, 93••] and that FcγRs may mediate tumour ADCC [16]. Therefore, it is likely that polymorphisms in human FcγR genes may contribute to differential susceptibility and prognosis in patients with post-transplant malignancy. Indeed, in non-transplant patients with B-cell lymphoma, an increased prevalence of the low-affinity FcγRIIA-131R/R genotype was observed in subjects with Epstein-Barr virus infection.
latency and with expression of oncogenic latency proteins [94, 95]. There is also a wealth of evidence demonstrating that activating FcγR polymorphisms can profoundly influence the efficacy of therapeutic monoclonal antibodies used for the treatment of malignancies, including the effect of rituximab in lymphomas [96].

**Atherosclerosis**

Evidence suggests that antibodies can be both protective and pathogenic; immunisation with oxLDL reduces atherosclerosis in murine models, likely due to the protective effects of oxLDL-specific antibodies [17, 18]. In addition, intravenous immunoglobulin which contains a mixture of polyclonal IgG from multiple human donors, is also protective in animal models of atherosclerosis [97], and this effect is dependent on the Fc region of IgG [98, 99]. In contrast, other studies suggest that the inhibitory receptor FcγRIIB regulates their pathogenic effects; both apo-E and LDLR-deficient mice develop a more severe disease in the absence of FcγRIIB [106, 107]. These data raise the possibility that functionally significant genetic variants of this receptor in humans might contribute to atheroma susceptibility. A significant association with the rs396991 SNP in FcγRIIA was demonstrated in one study; patients homozygous for the FcγRIIA-V158 allele (encoding a receptor with a high affinity for IgG) had a significantly reduced risk of CAD compared with FcγRIIA-F158 homozygotes [108].

**Conclusion**

FcγRs play an important role in mediating many effector functions of IgG and genetic variation in these receptors and may have a complex impact on outcomes in solid organ transplantation (Fig. 2). The binding of graft-deposited alloantibodies to activating FcγRs on neutrophils, monocytes, macrophages and NK cells may result in inflammation, however could potentially facilitate clearance with minimal inflammation, depending on whether there is co-engagement of FcγRIIB. Furthermore, activating receptor variants with higher affinity for IgG might also improve outcomes in infection and malignancy. This complex balance requires further investigation in solid organ transplantation, particularly before efforts to target these receptors are applied therapeutically.

**Acknowledgments**

TCD is a University of Cambridge/Wellcome Trust Infection, Immunity and Inflammation PhD student. MRC is supported by the NIHR Cambridge BRC, the NIHR Blood and Transplant Research Unit (Cambridge) and by a Medical Research Council New Investigator Grant (MR/N024907/1).

**Compliance with Ethical Standards**

**Conflict of Interest**

Menna Clatworthy and Tomas Castro-Dopico declare no conflict of interest.

**Human and Animal Rights and Informed Consent**

This article does not contain any studies with human or animal subjects performed by any of the authors.

**Open Access**

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

Papers of Particular Interest, Published recently, Have Been Highlighted as
- Of importance
- Of major importance

1. Nimmerjahn F, Ravetch JV. Fcg receptors as regulators of immunity. Adv Immunol. 2007;96:179–204.
2. Pincetic A et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol. 2014;15(8):707–16.
3. Clatworthy MR, Smith KG. B cells in glomerulonephritis: focus on lupus nephritis. Semin Immunopathol. 2007;29(4):337–53.
4. Cui Z, Zhao MH. Advances in human antiglomerular basement membrane disease. Nat Rev Nephrol. 2011;7(12):697–705.
5. Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012;8(6):348–57.
6. Loupy A, Jordan SC. Transplantation: donor-specific HLA antibodies and renal allograft failure. Nat Rev Nephrol. 2013;9(3):130–1.
7. Jolly EC et al. Preformed donor HLA-DP-specific antibodies mediate acute and chronic antibody-mediated rejection following renal transplantation. Am J Transplant. 2012;12(10):2845–8.
8. Loupy A et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369(13):1215–26.
9. Hidalgo LG et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant. 2009;9(11):2532–41.
10.Einecke G et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009;9(11):2520–31.
11. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant. 2010;15(1):42–8.
12. Haas M et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272–83.
13. Spiegelberg HL. Biological role of different antibody classes. Int Arch Allergy Appl Immunol. 1989;90(Suppl 1):22–7.
14. Jindra PT et al. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol. 2008;180(4):2357–66.
15. Clatworthy, M.R., Fcy Receptor polymorphisms and susceptibility to infection, in Antibody Fc. Linking adaptive and innate immunity. M.E.N. Ackerman, F. Editor. 2014, Academic Press, Elsevier. p. 217–238.
16. Clynes RA et al. Inhibitory Fcg receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443–6.
17. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A. 1995;92(3):821–5.
18. Zhou X et al. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21(1):108–14.
19. Kiener PA et al. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol. 1993;13(7):990–9.
20. Smith KGC, Clatworthy MR. FcyRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;10(5):328–43.
21. Bhuradwaj D et al. The major receptor for C-reactive protein on leucocytes is fcygamma receptor II. J Exp Med. 1999;190(4):585–90. Demonstration that FcyRs can not only bind IgG but can also bind acute phase response proteins, broadening their potential role in both inflammation and defence against infection.
22. Bhuradwaj D et al. Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis. J Immunol. 2001;166(11):6735–41.
23. Pricop L et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol. 2001;166(1):531–7.
24. Liu Y et al. Cytokine-mediated regulation of activating and inhibitory Fc gamma receptors in human monocytes. J Leukoc Biol. 2005;77(5):767–76.
25. Anthony RM et al. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;475(7354):110–3 Demonstration of the importance of, and one of the mechanisms by which, IgG sialylation can promote immunoregulation by ligating DC–SIGN and inducing IL33 production to enhance basophil IL4 secretion, culminating in the upregulation of FcyRIIB on effector macrophages.
26. Boruchov AM et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest. 2005;115(10):2914–23.
27. Wilcock L, Smith KG, Clatworthy MR. Low-affinity Fcg receptors, autoimmunity and infection. Expert Rev Mol Med. 2009;11:24.
28. Shields RL et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgRIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733–40.
29. Ferrara C et al. The carbohydrate at FcgRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem. 2006;281(8):5032–6.
30. Arnold JN et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.
31. Lux A, Nimmerjahn F. Impact of differential glycosylation on IgG activity. Adv Exp Med Biol. 2011;780:113–24.
32. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005;310(5753):1510–2.
33. Vuckovic, F., et al., Systemic lupus erythematosus associates with the decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol. 2015.
34. Albrecht S et al. Glycosylation as a marker for inflammatory arthritis. Cancer Biomark. 2014;14(1):17–28.
35. Daeron M. Fc receptor biology. Annu Rev Immunol. 1997;15:203–34.
36. Ono M et al. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcgRIIB. Nature. 1996;383(6597):263–6.
37. Pan LF, Kreisle RA, Shi YD. Detection of Fcg receptors on human endothelial cells stimulated with cytokines tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma). Clin Exp Immunol. 1998;112(3):533–8.
38. van Mirre E et al. Neutrophil responsiveness to IgG, as determined by fixed ratios of mRNA levels for activating and inhibitory FcgRII (CD32), is stable over time and unaffected by cytokines. Blood. 2006;108(2):584–90.
39. Wilcocks LC et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J Exp Med. 2008;205(7):1573–82. First investigation of a human subject with FcγRIIB-deficiency demonstrating the importance of this receptor in immune complex uptake by neutrophils.
40. Ericson JA et al. Gene expression during the generation and activation of mouse neutrophils: implication of novel functional and regulatory pathways. PLoS One. 2014;9(10):e108553.
41. Rosales C, Brown EJ. Signal transduction by neutrophil immunglobulin G Fc receptors. Dissociation of intracytoplasmic calcium concentration rise from inositol 1,4,5-trisphosphate. J Biol Chem. 1992;267(8):5265–71.
42. Zhou MJ, Brown EJ. CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RI coordinates in generation of a neutrophil respiratory burst: requirement for Fc gamma RII and tyrosine phosphorylation. J Cell Biol. 1994;125(6):1407–16.
43. Coxon A et al. FcγRIIB mediates neutrophil recruitment to immune complexes: a mechanism for neutrophil accumulation in immune-mediated inflammation. Immunol. 2001;14(6):693–704.
44. Kessenbrock K et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623–5.
45. Mayadas TN, Tsokos GC, Tsboi N. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation. 2009;120(20):2012–24.
46. Sur Chowdhury C et al. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther. 2014;16(3):R122.
47. Guiliams M et al. The function of Fcg receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14(2):94–108.
48. Clynes R et al. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fcg receptors. J Exp Med. 1999;189(1):179–85.
49. Yuasa T et al. Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med. 1999;189(1):187–94.
50. Clatworthy MR, Smith KG. FcgRIIB balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis. J Exp Med. 2004;199(5):717–23.
51. Brownlie RJ et al. Distinct cell-specific control of autoimmunity and infection by FcgRIIB. J Exp Med. 2008;205(4):883–95.
52. Regnault A et al. Fcg receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med. 1999;189(2):371–80.
53. de Jong JM et al. Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo. Immunology. 2006;119(4).

54. Clatworthy, M.R., et al., Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes. Nat Med. 2014. 20(12): p. 1458–63. First demonstration that FcyR cross-linking by IC can alter the migratory behaviour of DCs.

55. Dhodapkar KM et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A. 2005;102(8):2910–5.

56. Dhodapkar KM et al. Selective blockade of inhibitory FcgammaRIIB signaling. J Immunol. 2012;189(12):5694–702.

57. Titus JA et al. Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol. 1987;139(9):3153–8.

58. Metes D et al. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcgammaRIIC gene. Blood. 1998;91(7):2369–80.

59. Xiang Z et al. FcgRIIB controls bone marrow plasma cell persistence and apoptosis. Nat Immunol. 2007;8(4):419–29.

60. Buan H et al. Anti-HLA antibody ligation to HLA class I molecules expressed by endothelial cells stimulates tyrosine phosphorylation, inositol phosphate generation, and proliferation. Hum Immunol. 1997;53(1):90–7.

61. Jindra PT et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation. 2006;82(1 Suppl):S33–5.

62. Valenzuela NM et al. Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcgRIIA polymorphisms. Am J Transplant. 2015;15(6):1502–18.

63. Dewar S, Du Clos TW, Jalal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol. 2005;25(7):1359–63.

64. Sundgren NC et al. IgG receptor FcgammaRIIB plays a key role in obesity-induced hypertension. Hypertension. 2015;65(2):456–62.

65. Suvanichkul A, Wunderer SE. Differential expression of functional Fc-receptors and additional immune complex receptors on mouse kidney cells. Mol Immunol. 2015;56(4):369–70.

66. Callaghan CJ et al. Regulation of allograft survival by inhibitory FcgammaR1IIB signaling. J Immunol. 2012;189(12):5694–702. This study demonstrates the importance of inhibitory FcyRIIB in a murine cardiac allograft model through the suppression of alloantibody generation.

67. Sharp PE et al. FcgRIIB on myeloid cells and intrinsic renal cells rather than B cells protects from nephrotic nephritis. J Immunol. 2013;190(1):340–8.

68. Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int. 2003;63(5):1888–93.

69. Tinckam KJ, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int. 2005;68(4):1866–74.

70. Xu L et al. Increased macrophage density of cardiac allograft biopsies is associated with antibody-mediated rejection and alloantibodies to HLA antigens. Clin Transpl. 2014;28(5):554–60.

71. Hidalgo LG et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant. 2010;10(8):1812–22.

72. Hidalgo LG et al. Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant. 2012;12(5):1180–91.

73. Kerjaschi D et al. Lymphatic neangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol. 2004;15(3):603–12.

74. Clatworthy MR et al. FcgRIIB inhibits immune complex-induced VEG-F production and intranodal lymphangiogenesis. Proc Natl Acad Sci U S A. 2014;111(50):17971–6.

75. Venner JM et al. The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant. 2015;15(5):1336–48. This paper demonstrates an association between ABMR and FcyR-associated transcripts in renal transplant biopsies, implicating ADCC as a driver of allograft rejection.

76. Pawlik A et al. The correlation between FcgRIIA polymorphism and renal allograft survival. Transplant Proc. 2002;34(8):3138–9.

77. Pawlik A et al. The FcgRIIA polymorphism in patients with chronic kidney graft rejection. Transplant Proc. 2004;36(5):1311–3.

78. Yuan FF et al. Association of Fcg receptor IIIA polymorphisms with acute renal-allograft rejection. Transplantation. 2004;78(5):766–9.

79. Ozkayin N, Mir S, Afig B. The role of fggamma receptor gene polymorphism in pediatric renal transplant rejections. Transplant Proc. 2008;40(10):3367–74.

80. Arnold ML et al. Association of a coding polymorphism in Fcg receptor 2A and graft survival in re-transplant candidates. Hum Immunol. 2015;76(10):759–66.

81. Floto RA et al. Loss of function of a lupus-associated FcgRIIB polymorphism through exclusion from lipid rafts. Nat Med. 2005;11(10):1056–8. First demonstration of the mechanism by which a transmembrane domain amino acid substitution leads to a failure of inhibitory function of FcyRIIB, providing an explanation for the association of this SNP with SLE susceptibility.

82. Kono H et al. FcgRIIB Ile232Thr transmembrane polymorphism associates with acute renal-allograft rejection. Transplant Proc. 2004;36(5):1311–3.

83. Willcocks LC et al. A defunctioning polymorphism in FCGR2B is associated with susceptibility to infectious complications after liver transplantation. Am J Transplant. 2010;10(8):1812–22.
FcγR genes as risk factors for infection and mortality in patients following liver transplantation, attributed to diminished CRP binding.

91. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcg receptors on dendritic cells. J Exp Med. 2002;195(12):1653–9.

92. Schuurhuis DH et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol. 2006;176(8):4573–80.

93. Carmi Y et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature. 2015;521(7550):99–104. Elegant demonstration of the potential of IgG to promote an immune response that inhibits a variety of different tumour types in vivo, via FcγR-dependent DC activation.

94. Diamantopoulos PT et al. Correlation of FcgRIIA polymorphisms with latent Epstein-Barr virus infection and latent membrane protein 1 expression in patients with low grade B-cell lymphomas. Leuk Lymphoma. 2013;54(9):2030–4.

95. Ghesquieres H et al. FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. Leuk Lymphoma. 2013;54(11):2571–3.

96. Mellor JD et al. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol. 2013;6:1.

97. Nicoletti A et al. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest. 1998;102(5):910–8.

98. Yuan Z et al. Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am J Physiol Heart Circ Physiol. 2003;285(2):H899–906.

99. Okabe TA et al. Effects of late administration of immunoglobulin on experimental atherosclerosis in apolipoprotein E-deficient mice. Circ J. 2005;69(12):1543–6.

100. Burut DF, Karim Y, Ferns GA. The role of immune complexes in atherogenesis. Angiology. 2010;61(7):679–89.

101. Ait-Oufella H et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 2010;207(8):1579–87.

102. Hernandez-Vargas P et al. Fcg receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ Res. 2006;99(11):1188–96.

103. Kishimoto C. A novel approach to the suppression of atherosclerosis by Fcg receptor blockade. Circ Res. 2006;99(11):1154–5.

104. Kelly JA et al. Inhibition of arterial lesion progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10. Cardiovasc Res. 2010;85(1):224–31.

105. Ng HP, Burris RL, Nagarajan S. Attenuated atherosclerotic lesions in apo-E-Fcg-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells. J Immunol. 2011;187(11):6082–93.

106. Zhao M et al. FcgRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice. J Immunol. 2010;184(5):2253–60.

107. Mendez-Fernandez YV et al. The inhibitory FcgRIIB modulates the inflammatory response and influences atherosclerosis in male apoE(−/−) mice. Atherosclerosis. 2010;214(1):73–80.

108. Gavasso S et al. Fcg receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis. 2005;180(2):277–82.